MK-6552 + diltiazem

**MK-6552 + diltiazem** is a combination of two small molecule drugs, administered together in clinical pharmacology studies to assess possible pharmacokinetic interactions and safety profiles. MK-6552 is under investigation as a treatment for narcolepsy type 1, with a mechanism that is not publicly disclosed, but it is being developed by Merck Sharp & Dohme. Diltiazem is a long-approved calcium channel blocker, often used to treat hypertension, angina, and certain arrhythmias, functioning as a non-dihydropyridine L-type calcium channel (CACNA1C) inhibitor. The combination is currently being studied in healthy adult participants to evaluate effects on drug levels and potential drug-drug interactions[1][3][8].